Dr. Altagrace Hanley, medical director at La Boussole Medical Spa & Wellness Center, has achieved board certification in ...
US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...
In this video, Jamy D. Ard, MD, FTOS, discusses treatment options, lifestyle interventions and strategies for patients with obesity.
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
To address this, American pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven effective in managing both obesity and type-2 diabetes.
The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...